⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CTNM News
Contineum Therapeutics, Inc. Class A Common Stock
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
CTNM
Contineum Therapeutics to Present at the 2026 RBC Capital Markets Global Healthcare Conference
businesswire.com
CTNM
Contineum Therapeutics Announces Two Upcoming Posters at the American Thoracic Society (ATS) 2026 International Conference
businesswire.com
CTNM
Form 8-K
sec.gov
CTNM
Contineum Therapeutics Reports First-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones
businesswire.com
CTNM
Contineum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
CTNM
Contineum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
CTNM
Form 8-K
sec.gov
CTNM
Contineum Therapeutics Reports Positive Topline Data From Its Exploratory PIPE-791 Phase 1b Trial in Chronic Pain
businesswire.com
CTNM
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
CTNM